LONDON, December 9 /PRNewswire/ -- For its dedication in producing a full spectrum of downstream processing products and services through technical innovation and industrial collaboration, Frost & Sullivan confers the 2004 Product Differentiation Innovation Award in the arena of biopharmaceutical production on Sartorius AG, Biotech Division.
"Sartorius Purification Technologies has been commended for its ability to offer superior application development services in tandem with developing a range of bioprocess technology, with a particular focus on downstream processing," says Frost & Sullivan Research Analyst Phil Webster.
Realising the need to provide the biopharmaceuticals industry with an integrated portfolio of technology products, Sartorius has worked to build a truly comprehensive and integrated solution. This includes the provision of fermentation, separation and automation systems as well as training and validation support.
Powerful technologies for cell removal at high biomass, bioseparation strategies on the basis of membrane adsorbers as well as an orthogonal platform for the reliable removal of pathogens and other process-derived contaminants have underlined Sartorius Purification Technologies' innovations in the downstream processing arena.
Sartorius' commitment to product diversification is evident in its annual investments of USD 25,2 million in technology R&D (2003). Reinforcing this has been the company's continual focus on achieving high levels of consistency, accessibility and equipment support of its diverse technology offerings at a global level.
The collaboration between Bayer Technology Services and Sartorius Purification Technologies has optimally welded two benchmark downstream processing portfolios. "Bayer Technology Services' expertise in process technology, combined with Sartorius' experience in membrane-based separation systems are a true and outstanding demonstration of product differentiation," elaborates Mr. Webster.
The diverse technology platform, establishment of a global sales and support network and the formation of strategic alliances with complementary service and technology providers such as KMI/Parexel, USA, TC Tech, USA and Bayer Technology Services, Germany have effected sales of nearly USD 250 million in the biopharmaceutical sector, which is credited primarily to biomanufacturing technology.
In choosing the recipient of this award, Frost & Sullivan analysts tracked product differentiation strategies of competing market participants through company interviews, end-user surveys and extensive secondary research.
Degree of differentiation innovation compared to other market participants, positive impact on sales directly related to product differentiation, time to market improvement based upon product differentiation strategy, benefit to end users due to product uniqueness and effect of product differentiation on ease of adaptability for new end-user applications as well as on market maturation were among the measurement criteria used to rank market participants.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company founded in 1961, partners with clients to create value through innovative growth strategies. The foundation of this partnership approach is our Growth Partnership Services platform, whereby we provide industry research, marketing strategies, consulting and training to our clients to help grow their business. A key benefit that Frost & Sullivan brings to its clients is a global perspective on a broad range of industries, markets, technologies, econometrics, and demographics. With a client list that includes Global 1000 companies, emerging companies, as well as the investment community, Frost & Sullivan has evolved into one of the premier growth consulting companies in the world.
Frost & Sullivan,
Frost & Sullivan